Monoclonal antibodies are emerging as one of the most promising non-addictive alternatives to opioids for chronic pain, working by intercepting pain signals before they ever reach the brain. Four such antibodies targeting calcitonin gene-related peptide, or CGRP, have already earned FDA approval for migraine prevention — erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), and eptinezumab (Vyepti) — and researchers are now developing next-generation versions that target entirely different pain pathways, including the sodium channels and nerve growth factors that drive osteoarthritis, neuropathic pain, and other chronic conditions. For the more than 50 million Americans living with chronic pain, and for the families and caregivers of older adults whose cognitive health is eroded by persistent, undertreated pain, these therapies represent a genuine shift in what pain management could look like. This matters deeply in the context of brain health and dementia care.
Chronic pain is both underdiagnosed and undertreated in people with cognitive decline, and prolonged opioid use carries its own neurocognitive risks. A treatment that could be self-injected once a month, that doesn’t cross readily into addictive territory, and that leaves normal sensation intact would change the calculus for millions of older adults and their care teams. This article covers what CGRP monoclonal antibodies have already achieved, why the anti-nerve growth factor approach hit serious safety roadblocks, how experimental sodium channel antibodies could become the next breakthrough, and what all of this means for people navigating pain alongside dementia or age-related cognitive change. The science is moving quickly, but it is not without setbacks and limitations. Understanding where these therapies actually stand — not where press releases suggest they stand — is essential for making informed decisions about care.
Table of Contents
- How Do Monoclonal Antibodies Block Chronic Pain Signaling at the Source?
- CGRP Antibodies for Migraine and Beyond — What the Evidence Actually Shows
- Why Anti-Nerve Growth Factor Antibodies Failed to Win Approval
- Sodium Channel Antibodies — A Non-Addictive Alternative to Opioids?
- Pain, Cognitive Decline, and the Hidden Cost of Undertreated Pain in Dementia
- Other Monoclonal Antibody Targets Under Investigation for Chronic Pain
- What Comes Next for Monoclonal Antibodies and Chronic Pain Management
- Conclusion
- Frequently Asked Questions
How Do Monoclonal Antibodies Block Chronic Pain Signaling at the Source?
Traditional painkillers, whether over-the-counter NSAIDs or prescription opioids, tend to work by dampening the brain’s perception of pain after the signal has already arrived. Monoclonal antibodies take a fundamentally different approach. They are engineered proteins designed to bind to specific molecules involved in pain transmission — intercepting the signal at or near its origin in peripheral nerves, before it can cascade through the spinal cord and into the brain. The CGRP antibodies, for example, neutralize calcitonin gene-related peptide, a molecule released by the trigeminal nerve system that plays a central role in migraine pathology. By binding either to CGRP itself or to its receptor, these antibodies prevent the inflammatory and pain-signaling cascade from ever fully activating. this source-level intervention is what distinguishes monoclonal antibodies from conventional pain medications.
Opioids bind to receptors throughout the central nervous system, producing analgesia but also sedation, tolerance, dependence, and cognitive impairment — side effects that are particularly dangerous for older adults and people with dementia. CGRP antibodies, by contrast, operate largely in the peripheral nervous system. The American Headache Society now recommends them as first-line preventive therapy for migraine, a designation that reflects both their efficacy and their comparatively clean side effect profile. Long-term postmarketing safety data published in 2024 and 2025 confirms that adverse reactions are primarily nonserious, including fatigue and injection site reactions, though hypertension has been flagged as a potential side effect, particularly within the first week after injection. For caregivers and clinicians managing pain in cognitively impaired patients, the distinction matters. A therapy that does not sedate, does not impair cognition, and does not create dependence addresses several of the most pressing concerns in geriatric pain management simultaneously.
CGRP Antibodies for Migraine and Beyond — What the Evidence Actually Shows
The clinical track record of CGRP monoclonal antibodies is, by the standards of pain medicine, remarkably strong. All four approved agents have demonstrated meaningful reductions in monthly migraine days in large randomized controlled trials, and galcanezumab has also received FDA approval for the prevention of episodic cluster headache — one of the most severe pain conditions known. These are not marginal improvements. For patients who had previously cycled through antidepressants, beta-blockers, and anticonvulsants with limited relief, CGRP antibodies have provided the first real reduction in headache burden. However, these therapies are not universally effective. Roughly 30 to 50 percent of patients in clinical trials did not achieve a 50 percent or greater reduction in migraine days, and the antibodies are approved specifically for migraine and cluster headache — not for chronic pain broadly.
Applying them off-label to other pain conditions without evidence is a mistake that clinicians and patients should avoid. There is also the question of cost and access. CGRP monoclonal antibodies are expensive, often running several hundred dollars per injection without insurance, and prior authorization requirements can delay treatment for months. Emerging research is beginning to explore CGRP blockade for other pain conditions. In mouse models, fremanezumab and galcanezumab reduced both endometriosis pain and lesion size, suggesting that the CGRP pathway may be involved in visceral and inflammatory pain beyond headache. But animal models are not human trials, and it would be premature to treat these findings as clinical evidence. The honest summary: CGRP antibodies are a proven, first-line option for migraine prevention, a plausible candidate for expansion into other pain types, and not yet a general-purpose chronic pain treatment.
Why Anti-Nerve Growth Factor Antibodies Failed to Win Approval
The story of tanezumab is a cautionary tale about the gap between a compelling biological rationale and a safe, approvable therapy. Developed by Pfizer and Eli Lilly, tanezumab is a monoclonal antibody that binds nerve growth factor, or NGF — a protein that sensitizes pain receptors and amplifies pain signaling in conditions like osteoarthritis and chronic low back pain. The idea was straightforward: block NGF, and you block both peripheral and central sensitization at the source. The FDA granted tanezumab Fast Track designation for chronic pain due to moderate-to-severe osteoarthritis, a signal that regulators recognized the unmet need. But the clinical trial data revealed a serious problem. Patients receiving tanezumab developed rapidly progressive osteoarthritis at rates that alarmed regulators — joint space narrowing of two millimeters or more per year, chondrolysis, and outright bone destruction, all appearing as dose-dependent adverse effects.
In March 2021, an FDA Advisory Committee voted 19 to 1 against approval, concluding that the proposed risk evaluation and mitigation strategy was insufficient to ensure that benefits outweighed risks. Six months later, the European Medicines Agency recommended refusal of marketing authorization as well. As of 2026, no anti-NGF monoclonal antibody — not tanezumab, nor fulranumab, nor fasinumab — has received FDA approval for chronic pain. The failure of anti-NGF antibodies carries a specific lesson for patients and caregivers in the dementia space. Osteoarthritis is extraordinarily common in older adults, and the desire for better pain control in people who cannot tolerate opioids is urgent. But a treatment that accelerates joint destruction in the very population it was designed to help is worse than no treatment at all. The biological logic of blocking NGF remains sound, but the therapeutic window may be too narrow for safe clinical use — at least with current approaches.
Sodium Channel Antibodies — A Non-Addictive Alternative to Opioids?
The most exciting frontier in monoclonal antibody pain research targets the voltage-gated sodium channels NaV1.7, NaV1.8, and NaV1.9 — ion channels that are critical for transmitting pain signals from peripheral nerves to the spinal cord. The foundational insight comes from human genetics: individuals born with nonfunctional NaV1.7 channels do not feel pain. They can sense temperature, pressure, and other stimuli normally, but the pain signal simply does not fire. Researchers Vladimir Yarov-Yarovoy and James Trimmer at UC Davis have been developing monoclonal antibodies that selectively block these channels, supported by a $1.5 million NIH HEAL Initiative grant — part of the federal effort to combat the opioid crisis. In 2025, the team reported a significant preclinical breakthrough. Novel humanized anti-NaV1.7 antibodies demonstrated high binding affinity and selectivity in rat models of neuropathic pain using partial sciatic nerve ligation. Systemic administration produced analgesic effects lasting at least 96 hours, and critically, the treatment did not impair normal pain sensation or motor function. This last point is essential.
A pain therapy that eliminates protective pain — the ability to feel a burn, a broken bone, a heart attack — would be dangerous. The fact that these antibodies appear to modulate pathological pain while preserving physiological pain is what makes the approach viable. The comparison with opioids is stark. Opioids act on the central nervous system, producing tolerance, physical dependence, respiratory depression, and cognitive impairment. Monoclonal antibodies can circulate in the bloodstream for over a month, meaning patients could potentially self-inject once monthly for sustained relief. They do not cross the blood-brain barrier easily, which limits both their central nervous system side effects and their abuse potential. For older adults with chronic neuropathic pain — a population that overlaps heavily with dementia and pre-dementia — a monthly injection that controls pain without sedation or cognitive fog would be transformative. But these antibodies remain in preclinical development, and the path from rat models to FDA approval is long and uncertain.
Pain, Cognitive Decline, and the Hidden Cost of Undertreated Pain in Dementia
Chronic pain and dementia share a destructive bidirectional relationship that is often invisible to the systems designed to treat either condition alone. Persistent pain impairs attention, disrupts sleep, increases agitation and behavioral disturbances, and accelerates functional decline in people with Alzheimer’s disease and other dementias. At the same time, cognitive impairment makes pain harder to recognize, report, and treat — creating a cycle in which pain worsens cognition and cognitive decline worsens pain management. The standard pharmacological toolkit for chronic pain in dementia is limited and problematic. Opioids carry well-documented risks of sedation, falls, delirium, and respiratory depression in older adults. NSAIDs are associated with gastrointestinal bleeding and renal impairment.
Acetaminophen is safer but often insufficient for moderate to severe pain. This is why the development of monoclonal antibodies for chronic pain has implications that extend well beyond headache medicine. A therapy that blocks pain signaling peripherally, without sedating or cognitively impairing the patient, addresses the precise gap that makes pain management in dementia so difficult. There is, however, an important limitation to acknowledge. None of the currently approved CGRP antibodies have been studied specifically in populations with dementia. Clinical trials for these therapies generally excluded patients with significant cognitive impairment. Whether the safety and efficacy profiles observed in younger, cognitively intact migraine patients translate directly to older adults with Alzheimer’s disease remains an open question — one that deserves dedicated research attention.
Other Monoclonal Antibody Targets Under Investigation for Chronic Pain
CGRP, NGF, and sodium channels are not the only molecular targets being explored. Monoclonal antibodies directed against tumor necrosis factor (TNF) and interleukin-6 (IL-6) are under investigation for chronic pain conditions including rheumatoid arthritis and chronic low back pain. TNF and IL-6 are inflammatory cytokines that contribute to pain sensitization, and biologic therapies targeting these molecules are already approved for autoimmune conditions — the question is whether they can be repurposed or refined specifically for pain relief.
For patients and caregivers, the broader lesson is that monoclonal antibody pain research is not a single story with a single molecule. It is a rapidly diversifying field with multiple targets, multiple mechanisms, and different risk-benefit profiles for different conditions. A therapy that fails for osteoarthritis pain (like tanezumab) may have no bearing on the success of a therapy targeting sodium channels for neuropathic pain. Watching only one development and generalizing to the whole field would be a mistake.
What Comes Next for Monoclonal Antibodies and Chronic Pain Management
The trajectory of this field over the next several years will likely be defined by two questions. First, can the sodium channel antibodies in preclinical development replicate their promising results in human trials without the kind of safety signals that derailed anti-NGF therapies? The 96-hour analgesic effect observed in rat models is encouraging, and the month-long circulation time of monoclonal antibodies makes a once-monthly injection plausible — but human pharmacokinetics, immunogenicity, and long-term safety remain unknowns.
Second, will the research community and funding agencies prioritize studying these therapies in the populations that need them most, including older adults with concurrent pain and cognitive decline? The NIH HEAL Initiative grant supporting the UC Davis sodium channel work is a positive sign, and the sheer scale of the problem — over 50 million Americans with chronic pain, an aging population with rising dementia prevalence, and an opioid crisis that has made the status quo untenable — creates strong incentive. For families navigating dementia care, staying informed about these developments is not idle curiosity. It is preparation for a future in which pain management may look fundamentally different from what is available today.
Conclusion
Monoclonal antibodies represent a genuinely new approach to chronic pain — one that targets pain signaling molecules at their source rather than blunting the brain’s ability to perceive pain after the fact. The CGRP antibodies already on the market have proven this concept for migraine, earning first-line recommendation from the American Headache Society. The failure of anti-NGF antibodies like tanezumab demonstrates that not every biologically logical target translates into a safe therapy, while the preclinical success of sodium channel antibodies at UC Davis shows that the field is far from exhausting its possibilities. For people living with dementia-related challenges, the stakes of this research are particularly high.
Chronic pain is both a driver and a consequence of cognitive decline, and the current treatment options are poorly suited to a population vulnerable to sedation, falls, and drug-induced confusion. A monthly injection that controls pain without impairing cognition would not just improve comfort — it could slow functional decline, reduce behavioral disturbances, and ease the burden on caregivers. That therapy does not exist yet for most chronic pain conditions, but the scientific foundation is being laid now. Discussing emerging options with a neurologist or pain specialist, and asking specifically about CGRP antibodies for eligible headache conditions, is a reasonable step for any family managing pain alongside cognitive decline.
Frequently Asked Questions
Are CGRP monoclonal antibodies approved for chronic pain conditions other than migraine?
Not yet. The four FDA-approved CGRP antibodies — erenumab, galcanezumab, fremanezumab, and eptinezumab — are approved specifically for migraine prevention, and galcanezumab is also approved for episodic cluster headache. Research into CGRP blockade for other pain conditions like endometriosis is underway but remains in early stages.
Why was tanezumab rejected by the FDA despite targeting pain at its source?
An FDA Advisory Committee voted 19 to 1 against approval in March 2021 because tanezumab caused rapidly progressive osteoarthritis as a dose-dependent side effect — including joint space narrowing, chondrolysis, and bone destruction. The European Medicines Agency also recommended refusal. The benefits did not outweigh these serious joint safety risks.
Could monoclonal antibodies replace opioids for chronic pain?
That is the long-term goal of research programs like the NIH HEAL Initiative-funded work at UC Davis targeting sodium channel NaV1.7. Preclinical results in 2025 showed analgesic effects lasting at least 96 hours in rat models without affecting normal sensation. However, these therapies have not yet entered human trials, and the timeline to potential approval remains uncertain.
Are CGRP antibodies safe for older adults with dementia?
Postmarketing safety data shows that side effects of CGRP antibodies are primarily nonserious, including fatigue and injection site reactions, though hypertension has been noted in the first week after injection. However, clinical trials generally excluded patients with significant cognitive impairment, so their safety and efficacy in dementia populations has not been specifically established.
How often would a patient need to take monoclonal antibody pain treatment?
Current CGRP antibodies are administered monthly or quarterly depending on the specific drug. Monoclonal antibodies can circulate in the bloodstream for over a month, so future pain therapies using this approach would likely follow a similar once-monthly self-injection schedule.
What other pain targets are being explored with monoclonal antibodies?
Beyond CGRP, NGF, and sodium channels, researchers are investigating monoclonal antibodies targeting TNF (tumor necrosis factor) and IL-6 (interleukin-6) for conditions including rheumatoid arthritis and chronic low back pain. These inflammatory cytokines contribute to pain sensitization and represent additional potential intervention points.
